Loading search results
Do Docosahexaenoic and Eicosapentaenoic Acids Have Similar Effects on Inflammation Markers? A Systematic Review and Meta-analysis of Randomized Controlled Trials
Sponsor study identifier
observational
1
1 country
1
Study Start
April 16, 2018
Actual (reported)Primary Completion
February 1, 2020
Actual (reported)Study Completion
April 1, 2020
Actual (reported)According to the World Health Organization, cardiovascular diseases (CVDs) are the number 1 cause of death globally. Systemic and local tissue inflammation is now recognized as a key etiological process leading to CVD. Hence, elevated blood levels of inflammation markers are classified among the well-established risk factors for the development of CVD. Among nutritional strategies to prevent and/or reduce chronic inflammation, long-chain omega 3 PUFA (LCn-3PUFA), notably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have raised tremendous interest for their purported anti-inflammatory effects. Previous meta-analysis of randomized controlled trials (RCTs) substantiated the anti-inflammatory effect of LCn-3PUFA supplementation as evidenced by significant reductions in plasma concentrations of specific inflammation markers such as C-reactive protein (CRP) and tumor necrosis factor alpha (TNF-alpha). However, it is stressed that almost all of the reported RCTs have used a mix of EPA and DHA in various ratios, as EPA and DHA occur concomitantly and naturally in food (fish oils) and in most dietary supplements. Yet, several recent RCTs have recently been undertaken to test the hypothesis that not all LCn-3PUFAs are equal, at least when it comes to their anti-inflammatory effects. Accordingly, there is increasing interest and evidence for potential distinctive effects of DHA compared to EPA on systemic inflammation, raising the question: Is DHA a more potent anti-inflammatory nutrient than EPA? To formally answer this question, we will conduct a systematic review and meta-analysis of RCTs to assess and compare the individual anti-inflammatory effects of DHA and of EPA. The present work will be a pairwise and network meta-analysis focusing on RCTs comparing the effects of EPA and DHA on surrogate markers of systemic inflammation. The findings generated by these analyses will provide invaluable and timely comparative information on the specific efficacy of DHA and EPA as one of the key nutritional modalities for the treatment of chronic inflammation in high-risk men and women. This is important considering that LCn-3PUFA supplements are increasingly being used by the population and an ever growing market in the dietary supplements' industry.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 1, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 16, 2018
Actual (reported)April 17, 2018
Actual (reported)May 9, 2018
Actual (reported)February 1, 2020
Actual (reported)April 1, 2020
Actual (reported)Change in plasma concentration of CRP
Change in fasting plasma concentration of CRP with DHA vs. EPA or DHA vs. control or EPA vs. control
Baseline and up to 5 years
Change in plasma concentration of IL-6
Change in fasting plasma concentration of IL-6 with DHA vs. EPA or DHA vs. control or EPA vs. control
Baseline and up to 5 years
Change in plasma concentration of TNF-alpha
Change in fasting plasma concentration of TNF-alpha with DHA vs. EPA or DHA vs. control or EPA vs. control
Baseline and up to 5 years
Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
Adult population (18 years old and older) regardless of health status.
Institute of Nutrition and Functional Foods (INAF)
Québec, G1V 0A6, Canada
Vors C, Allaire J, Mejia SB, Khan TA, Sievenpiper JL, Lamarche B. Comparing the Effects of Docosahexaenoic and Eicosapentaenoic Acids on Inflammation Markers Using Pairwise and Network Meta-Analyses of Randomized Controlled Trials. Adv Nutr. 2021 Feb 1;12(1):128-140. doi: 10.1093/advances/nmaa086.
Vors C, Allaire J, Blanco Mejia S, Khan TA, Sievenpiper JL, Lamarche B. Reply to J Morze and L Schwingshackl. Adv Nutr. 2021 Feb 1;12(1):278-279. doi: 10.1093/advances/nmaa131. No abstract available.
Benoît Lamarche, PhD
Laval University
1 participants (actual enrollment reported by the registry).
First Submitted
April 17, 2018
First Posted
May 9, 2018
Study Start
April 16, 2018
Actual (reported)Change in plasma concentration of adiponectin
Change in fasting plasma concentration of adiponectin with DHA vs. EPA or DHA vs. control or EPA vs. control
Baseline and up to 5 years
Contact the study team to confirm eligibility.
Primary Completion
February 1, 2020
Actual (reported)Study Completion
April 1, 2020
Actual (reported)Last Updated
August 18, 2022
Record last verified: 2022-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: